19ACTIVITIES
1ORGS REPRESENTED
60BILLS
Organizations represented
1Orgs whose LD-2 filings list Samantha as an active lobbyist, sorted by activity volume.
Bills they file on
60S. 22965 mentions
S. 434 mentions
S. 7084 mentions
S. 10404 mentions
S. 10414 mentions
S. 10954 mentions
S. 10964 mentions
S. 10974 mentions
H.R. 8904 mentions
H.R. 15744 mentions
S. 6524 mentions
S. 8324 mentions
S. 8914 mentions
S. 9324 mentions
H.R. 9464 mentions
+ 45 more bills referenced in their activities
Topics in Filings
87Policy topics Samantha files on across all their LD-2 activities.
One Big Beautiful Bill Act×9
RESTORE Patent Rights Act×8
Inflation Reduction Act×8
Drug cost and pricing policy×8
Supply chain policy×8
Rural Development×6
Big Savings Act×5
Biopharmaceutical innovation policy×5
Skinny Labels×4
Affordable Prescriptions for Patients Act×4
Stop STALLING Act×4
Preserve Access to Affordable Generics and Biosimilars Act×4
Show all 87 topics (+75 more) ▾
Interagency Patent Coordination and Improvement Act×4
Bayh-Dole march-in rights policy×4
Patent thicket policy×4
AI patent policy×4
Patent eligibility policy×4
Post-grant proceeding policy×4
Patent submission policy×4
Modernizing and Ensuring PBM Accountability×4
Accountability, and Integrity Now and for the Future×4
User fee issues×4
Vaccine policy×4
Pharmacy Benefit Manager reform×4
Drug importation policy×4
FDA policy×4
Orphan Drug Act×4
Compounding policy×4
Clinical trial policy×4
Issues 340B drug discount program policy×4
Biosimilar approval and reimbursement policy×4
Artificial intelligence policy×4
Part D redesign and policy×4
Part B policy×4
Medicare rebate policy×4
Center for Medicare and Medicaid Innovation×4
Medicaid rebate policy×4
International intellectual property and market access policy×4
Pricing and reimbursement policy×4
WTO TRIPS waiver policy×4
China outbound investment policy×4
FDA Modernization×4
BIOSECURE Act×4
Most Favored Nation×4
Patent use codes policy×3
Give Kids a Chance Act×3
Antimicrobial resistance×3
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×3
Res. 566: Providing for consideration of the Senate amendment to the bill×3
Science, and Related Agencies Appropriations Act, 2026×3
Medication Affordability and Patent Integrity Act×3
Biosimilar Red Tape Elimination Act×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Insulin policy×2
Medicaid waiver policy×2
Stopping Pharmas Ripoffs and Drug Savings For All Act×2
Bipartisan Health Care Act×2
IRA price negotiation expansion policy×2
MAHA Commission Report×2
Make Our Children Healthy Again Competition policy×2
Issues 340B rebate pilot program Patient assistance program policy×2
Biosimilars Access and Affordability Act×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Saving Seniors Money on Prescriptions Act×1
Tariff policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
MVP Act×1
Legislative Branch×1
Patent fee policy×1
Open Payments Expansion Act×1
PBM Price Transparency and Accountability Act×1
Mikaela Naylon Give Kids a Chance Act×1
PBM Reform×1
HELP Copays Act×1
Antimicrobial resistance policy×1
GENErating cost Reductions for U.S×1
Medicare Against Rising Drugs Costs×1
US-UK Framework Agreement×1
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark4
Health Issues4
Medicare/Medicaid4
Trade (domestic/foreign)4
Budget/Appropriations3